Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from RETA

Robust demand, technological advancements, government and private investment, are fueling the biotech industry’s expansion and driving game-changing therapies and product development. With the industry anticipated to thrive, fundamentally strong biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and United Therapeutics (UTHR) look poised for substantial gains. Keep reading.

StockNews.com

Biogen Announces $7.3 Billion Acquisition After Outlining Plans To Cut 11% Of Workforce

Biogen says it has agreed to acquire Reata Pharmaceuticals for about $7.3 billion. Reata stock surged as Biogen stock gained ground.

Investors Business Daily

Reata Surges 12% Over Three Days; CEO Reflects On The Tricky Path To Launch A First-Ever Drug

Reata CEO Warren Huff says Friedreich's ataxia is "the worst disease." Now, RETA stock investors are watching the long-awaited drug launch.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Reata Nears Breakout After Snagging FDA Blessing To Launch Its Friedreich's Ataxia Drug

Reata Pharmaceuticals won the FDA's blessing to launch its Friedreich's ataxia drug, and RETA stock surged Wednesday.

Investors Business Daily

Top 1% Biotech Stock Reata Pharmaceuticals Faces Another Hurdle

Reata took a step closer to launching its highly anticipated Friedreich's ataxia drug on Friday with a new FDA filing, but RETA stock fell.

Investors Business Daily

Top 1% Biotech Reata Crashes On A Delay For Its Most Anticipated Drug

Reata scrapped a chronic kidney disease program and announced a delay for its first commercial product on Wednesday, and RETA stock crashed.

Investors Business Daily

Reata Pharma Stock Almost Triples After Winning 'Coin-Flip' FDA Approval

Reata won Food and Drug Administration approval for its neurological disease treatment and RETA stock almost tripled Wednesday.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Reata Stock Plummets As Official's Exit Shakes Up FDA's Neuroscience Unit

The FDA will decide whether to approve a neurological disease drug from Reata Pharmaceuticals this week, but RETA stock plummeted Monday.

Investors Business Daily

Recap: Reata Pharmaceuticals Q1 Earnings

Reata Pharmaceuticals (NASDAQ:RETA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Reata Pharmaceuticals Earnings Preview

Reata Pharmaceuticals (NASDAQ:RETA) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that Reata Pharmaceuticals will report an earnings per share (EPS) of $-2.15.

Benzinga

Reata Stock Enjoys A Two-Day Climb — Why It Could Still Be Facing Everest

U.S. officials will soon examine Reata's request to treat a neurodegenerative condition, and RETA stock continued its two-day climb Friday.

Investors Business Daily

Reata Pharmaceuticals's Return on Invested Capital Insights

Benzinga Pro data, Reata Pharmaceuticals (NASDAQ:RETA) reported Q4 sales of $934.00 thousand. Earnings fell to a loss of $85.39 million, resulting in a 18.84% decrease from last quarter.

Benzinga

People

Joseph Schwartz

17 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Regeneron Pharmaceuticals Inc

37 stories

Amylyx

35 stories

United Therapeutics Corporation

18 stories

Reata Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.